NASDAQ$PRCT

PROCEPT BioRobotics Corporation · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

PROCEPT BioRobotics reported strong first quarter results, driven by increased U.S. revenue and handpiece sales, and raised full year 2023 revenue guidance.

PROCEPT BioRobotics reported a 72% increase in total revenue to $24.4 million for Q1 2023, with U.S. revenue up 73%. The company's U.S. handpiece and consumable revenue increased by 165%. They have increased their full year 2023 revenue guidance to $128.0 million.

  • Total revenue for Q1 2023 was $24.4 million, a 72% increase year-over-year.
  • U.S. handpiece and consumables revenue increased by 165% to $11.8 million.
  • U.S. system and rental revenue increased by 13% to $8.8 million.
  • The company increased fiscal year 2023 total revenue guidance to $128.0 million.

Headline financials

Total Revenue

$24.4M

Previous: $14.2M+71.9%
EPS (adj)

-$0.63

Previous: -$0.39-61.5%
Gross Margin

51.0%

Previous: 54.0%-5.6%
U.S. Install Base

192

No prior period
Capital Expenditures

-$5.34M

Previous: -$55K-9607.3%
Free Cash Flow

-$33.8M

Previous: -$17.2M-96.2%
Net Income

-$28.5M

Previous: -$17.2M-65.7%
Operating Income

-$28.4M

Previous: -$15.7M-80.7%
Gross Profit

$12.5M

Previous: $7.69M+62.4%
Cash & Equivalents

$181M

Previous: $284M-36.3%
Total Assets

$284M

Previous: $321M-11.4%
Stock-Based Comp

$3.72M

Previous: $1.55M+139.9%

Revenue & EPS history

PROCEPT BioRobotics · Revenue · Quarterly

$24.4M

Q1 2023+71.9%vs Q1 2022
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

PROCEPT BioRobotics · $22.9M total across 4 segments · Q1 2023

  • U.S. Consumables
    $11.8M+164.9%
  • U.S. System Sales
    $8.77M+13.1%
  • Intl. System Sales
    $1.47M+98.0%
  • Intl. Consumables
    $906K+21.6%

Forward guidance

The Company projects revenue for the full year 2023 to be $128 million, which represents 71% growth over the Company’s prior year revenue. The Company projects full year 2023 gross margin to be approximately 54%. The Company projects full year 2023 total operating expense of approximately $167 million. The Company reiterates full year 2023 Adjusted EBITDA loss to be ($70.5) million.

Tailwinds

  • Revenue for the full year 2023 to be $128 million, which represents 71% growth over the Company’s prior year revenue.
  • Full year 2023 gross margin to be approximately 54%.
  • Sequential gross margin improvement was primarily attributable to increased operations and manufacturing efficiencies to absorb overhead expenses.
  • Received positive coverage policy decision from United Healthcare, effective June 1, 2023
  • Signed national sales contract with largest U.S. IDN on April 1, 2023

Headwinds

  • Full year 2023 Adjusted EBITDA loss to be ($70.5) million.
  • Operating expenses in the first quarter of 2023 were $40.9 million, compared with $23.4 million in the prior year period.
  • Net loss was $28.5 million for the first quarter of 2023, compared to a loss of $17.2 million in the prior year period.
  • Adjusted EBITDA was a loss of $23.9 million for the first quarter of 2023, compared to a loss of $13.5 million in the prior year period.
  • Gross margin for the first quarter 2023 was 51% compared to 54% in the prior year period

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+1.3%

Avg return

Earnings day

-0.2%

Avg return

5 days after

+0.6%

Avg return

30 days after

45%

10 / 22 earnings

Positive

+40.6%

Q3 2024

Best reaction

-15.2%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+10.7%+16.0%+21.3%
Q4 2025-15.2%-5.7%-5.3%
Q3 2025+1.6%-7.5%+2.7%
Q1 2025-5.6%+1.1%+3.0%
Q4 2024+8.6%-3.4%-4.2%
Q3 2024+40.6%+34.2%+41.5%
Q2 2024-9.4%-4.3%+24.8%
Q1 2024+16.5%+15.9%+25.3%
Q4 2023+1.1%+0.5%+1.2%
Q3 2023+21.7%+22.5%+39.5%
Q2 2023-6.7%-10.3%-18.4%
Q1 2023-15.0%-20.1%-10.9%
Q4 2022+1.2%-4.3%-28.7%
Q3 2022-9.9%-8.4%+5.8%
Q2 2022+4.3%+4.3%+0.2%
Q1 2022-5.1%-17.9%+19.5%
Q4 2021+1.2%+5.9%+38.7%
Q3 2020-2.2%-4.5%-28.0%
Q4 2020-2.2%-4.5%-28.0%
Q2 2021-2.2%-4.5%-28.0%
Q1 2021-2.2%-4.5%-28.0%
Q3 2021-4.4%-3.9%-29.6%
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro